Related references
Note: Only part of the references are listed.Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
Terri S. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
Pierre Bady et al.
ACTA NEUROPATHOLOGICA (2012)
Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients
Veronique Quillien et al.
CANCER (2012)
MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry
Sofia Mason et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice
Michael Weller et al.
NEURO-ONCOLOGY (2012)
A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts
Deborah S. Malley et al.
ACTA NEUROPATHOLOGICA (2011)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses
Artemis P. Vogazianou et al.
NEURO-ONCOLOGY (2010)
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
J. Dunn et al.
BRITISH JOURNAL OF CANCER (2009)
Prognostic Impact of O6-Methylguanine-DNA Methyltransferase Silencing in Patients With Recurrent Glioblastoma Multiforme Who Undergo Surgery and Carmustine Wafer Implantation A Prospective Patient Cohort
Philippe Metellus et al.
CANCER (2009)
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Koichi Ichimura et al.
NEURO-ONCOLOGY (2009)
Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic Astrocytomas
David T. W. Jones et al.
CANCER RESEARCH (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas
K. Ichimura et al.
ONCOGENE (2008)
Genomic analysis of pilocytic astrocytomas at 0.97 mb resolution shows an increasing tendency toward chromosomal copy number change with age
David T. W. Jones et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells
M Hermisson et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin
GW Xu et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
MJ van den Bent et al.
CANCER (2003)
Share Paper
